<DOC>
	<DOCNO>NCT02474667</DOCNO>
	<brief_summary>A Multicenter , Prospective , Double-Blind , Randomized , Placebo-Controlled , Phase 3 Study BB3 Reduce Severity Delayed Graft Function Recipients Deceased Donor Kidney . The major objective demonstrate safety efficacy BB3 reduce severity delay graft function ( DGF ) recipients high risk DGF receive decease donor renal allograft .</brief_summary>
	<brief_title>Reduce Severity DGF Recipients Deceased Donor Kidney</brief_title>
	<detailed_description />
	<mesh_term>Delayed Graft Function</mesh_term>
	<criteria>1 . All patient must provide write informed consent use Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) approve consent form , must understand willing able comply requirement study , include screen procedure require study visit . 2 . Males females â‰¥ 18 year age . 3 . Oligoanuric renal failure ( le 200 mL UO per day ) require hemodialysis peritoneal dialysis initiate least 3 month prior transplantation . 4 . Patient recipient first kidney transplant decease donor . 5 . Study drug administer start within 30 hour restoration blood flow engraft kidney . 6 . Body mass index &lt; 35 base dry weight . Dry weight height parameter obtain within 7 day prior study entry may used.. 7 . Estimated donor organ cold ischemia time le 30 hour ( PMP kidney le 40 hour ) . 8 . Females childbearing potential ( include perimenopausal woman menstrual period within 1 year ) : Must negative serum pregnancy test prior transplantation . Must agree use 2 form effective birth control regimen ( least onebarrier method ) initial 30day study period OR agree maintain total abstinence throughout initial 30day study period . 9 . Male patient must agree use condom suitable mean pregnancy prevention abstinence initial 30day study period . 10 . Patient poor renal function first 24 hour posttransplantation base average UO le 50 mL per hour 8 consecutive hour , maximize likelihood patient require dialysis within first 7 day posttransplant , irrespective pretransplant donor recipient risk factor . 11 . Reason low UO due structural vascular abnormality , indicate confirm renal ultrasound Doppler study and/or vascular urinary tract contrast study . Exclusion Criteria 1 . Signs symptoms volume depletion . 2 . Scheduled multiple organ transplantation prior recipient transplant organ . 3 . Recipient ABOincompatible kidney . 4 . Recipient pediatric enbloc kidney transplantation adult pediatric plan transplant dual kidney ( donor ) transplant en bloc . 5 . Recipient kidney preserve normothermic pulsatile machine perfusion . 6 . Has measurable donorspecific antibody positive crossmatch require desensitization prior transplantation deviation standard immunosuppressive therapy . 7 . Currently participate participate investigational drug medical device study within 30 day five drug halflives , whichever longer , prior enrollment study . Patients give another investigational agent course study ( Day 360 ) . Patients may participate another concurrent study study noninterventional , observational investigation . 8 . Concurrent sepsis active bacterial infection . 9 . Has active malignancy history solid , metastatic hematologic malignancy exception basal squamous cell carcinoma situ skin adequately treat . 10 . Female breastfeeding . 11 . History positive human immunodeficiency virus test . 12 . Requires treatment CYP1A2 inhibitor , ciprofloxacin and/or fluvoxamine . 13 . Unwilling unable comply protocol cooperate fully Investigator site personnel . 14 . Not deem medically appropriate study opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>DGF</keyword>
	<keyword>Delayed Graft Function</keyword>
	<keyword>Renal Transplantation</keyword>
	<keyword>Deseased Donor Kidney</keyword>
	<keyword>BB3</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Acute Kidney Injury</keyword>
</DOC>